Gilead Sciences Inc. (GILD)
Gilead Sciences: Diversification Strategy Not Derisked Enough Yet
Gilead Sciences: Diversification Strategy Not Derisked Enough Yet
Gilead Sciences to Report Q4 Earnings: Is a Beat in the Cards?
Investors' focus will likely be on GILD's HIV franchise performance and oncology sales when the company reports fourth-quarter 2024 results.
Ahead of Gilead (GILD) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics
Beyond analysts' top -and-bottom-line estimates for Gilead (GILD), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2024.
Gilead Sciences (GILD) Surpasses Market Returns: Some Facts Worth Knowing
Gilead Sciences (GILD) closed at $99.65 in the latest trading session, marking a +1.69% move from the prior day.
Gilead Sciences (GILD) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
Gilead (GILD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Gilead Sciences (GILD) Rises As Market Takes a Dip: Key Facts
In the most recent trading session, Gilead Sciences (GILD) closed at $98.38, indicating a +1.21% shift from the previous trading day.
Gilead: Strong Sales Growth Remains With Veklury And Beyond
Company sees strong growth in VEKLURY sales, driven by increased Covid-19 hospitalizations, with Q3 2024 sales up 9% to $692 million. LIVDELZI shows promise for long-term growth, with FDA Accelerated Approval for PBC and potential EMA approval in Q1 2025. TRODELVY sales increased by 17% year-over-year, with potential expansion into ES-SCLC and other Trop-2 expressing solid tumors.
Will Gilead (GILD) Beat Estimates Again in Its Next Earnings Report?
Gilead (GILD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Here is What to Know Beyond Why Gilead Sciences, Inc. (GILD) is a Trending Stock
Gilead (GILD) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Gilead Sciences (GILD) Stock Dips While Market Gains: Key Facts
In the most recent trading session, Gilead Sciences (GILD) closed at $93.85, indicating a -1.57% shift from the previous trading day.
Is It Worth Investing in Gilead (GILD) Based on Wall Street's Bullish Views?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
GILD vs. ALNY: Which Stock Is the Better Value Option?
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Gilead Sciences (GILD) and Alnylam Pharmaceuticals (ALNY). But which of these two stocks is more attractive to value investors?
